BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Barry GD, Suen JY, Le GT, Cotterell A, Reid RC, Fairlie DP. Novel Agonists and Antagonists for Human Protease Activated Receptor 2. J Med Chem 2010;53:7428-40. [DOI: 10.1021/jm100984y] [Cited by in Crossref: 84] [Cited by in F6Publishing: 85] [Article Influence: 6.5] [Reference Citation Analysis]
Number Citing Articles
1 Heo Y, Yang E, Lee Y, Seo Y, Ryu K, Jeon H, Namkung W. GB83, an Agonist of PAR2 with a Unique Mechanism of Action Distinct from Trypsin and PAR2-AP. IJMS 2022;23:10631. [DOI: 10.3390/ijms231810631] [Reference Citation Analysis]
2 Hsin L, Fernandopulle NA, Ding J, Lumb C, Veldhuis N, Karas JA, Northfield SE, Mackay GA. The effect of substance P and its common in vivo-formed metabolites on MRGPRX2 and human mast cell activation. Pharmacol Res Perspect 2022;10:e00990. [PMID: 35904495 DOI: 10.1002/prp2.990] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
3 Moudio S, Willis A, Pytka K, Abulkassim R, Brett RR, Webster JF, Wozny C, Barbour M, Jiang HR, Watson DG, van Kralingen JC, MacKenzie SM, Daniels M, McColl BW, Sossick S, Nuthall HN, Bushell TJ. Protease-activated receptor 2 activation induces behavioural changes associated with depression-like behaviour through microglial-independent modulation of inflammatory cytokines. Psychopharmacology (Berl) 2021. [PMID: 34888704 DOI: 10.1007/s00213-021-06040-1] [Reference Citation Analysis]
4 McIntosh KA, Cunningham MR, Bushell T, Plevin R. The development of proteinase-activated receptor-2 modulators and the challenges involved. Biochem Soc Trans 2020;48:2525-37. [PMID: 33242065 DOI: 10.1042/BST20200191] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 5.0] [Reference Citation Analysis]
5 Subramaniam S, Ogoti Y, Hernandez I, Zogg M, Botros F, Burns R, DeRousse JT, Dockendorff C, Mackman N, Antoniak S, Fletcher C, Weiler H. A thrombin-PAR1/2 feedback loop amplifies thromboinflammatory endothelial responses to the viral RNA analogue poly(I:C). Blood Adv 2021;5:2760-74. [PMID: 34242391 DOI: 10.1182/bloodadvances.2021004360] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
6 Humphries TLR, Shen K, Iyer A, Johnson DW, Gobe GC, Nikolic-Paterson D, Fairlie DP, Vesey DA. PAR2-Induced Tissue Factor Synthesis by Primary Cultures of Human Kidney Tubular Epithelial Cells Is Modified by Glucose Availability. Int J Mol Sci 2021;22:7532. [PMID: 34299151 DOI: 10.3390/ijms22147532] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
7 Seo Y, Heo Y, Jo S, Park SH, Lee C, Chang J, Jeon DK, Kim TG, Han G, Namkung W. Novel positive allosteric modulator of protease-activated receptor 1 promotes skin wound healing in hairless mice. Br J Pharmacol 2021;178:3414-27. [PMID: 33837955 DOI: 10.1111/bph.15489] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
8 Chandrabalan A, Ramachandran R. Molecular mechanisms regulating Proteinase‐Activated Receptors (PARs). FEBS J 2021;288:2697-726. [DOI: 10.1111/febs.15829] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 8.0] [Reference Citation Analysis]
9 Morais C, Rajandram R, Blakeney JS, Iyer A, Suen JY, Johnson DW, Gobe GC, Fairlie DP, Vesey DA. Expression of protease activated receptor-2 is reduced in renal cell carcinoma biopsies and cell lines. PLoS One 2021;16:e0248983. [PMID: 33765016 DOI: 10.1371/journal.pone.0248983] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
10 Iyer A, Humphries TLR, Owens EP, Zhao KN, Masci PP, Johnson DW, Nikolic-Paterson D, Gobe GC, Fairlie DP, Vesey DA. PAR2 Activation on Human Kidney Tubular Epithelial Cells Induces Tissue Factor Synthesis, That Enhances Blood Clotting. Front Physiol 2021;12:615428. [PMID: 33776786 DOI: 10.3389/fphys.2021.615428] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
11 McMahon DB, Carey RM, Kohanski MA, Adappa ND, Palmer JN, Lee RJ. PAR-2-activated secretion by airway gland serous cells: role for CFTR and inhibition by Pseudomonas aeruginosa. Am J Physiol Lung Cell Mol Physiol 2021;320:L845-79. [PMID: 33655758 DOI: 10.1152/ajplung.00411.2020] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
12 Pierre O, Fouchard M, Buscaglia P, Le Goux N, Leschiera R, Mignen O, Fluhr JW, Misery L, Le Garrec R. Calcium Increase and Substance P Release Induced by the Neurotoxin Brevetoxin-1 in Sensory Neurons: Involvement of PAR2 Activation through Both Cathepsin S and Canonical Signaling. Cells 2020;9:E2704. [PMID: 33348659 DOI: 10.3390/cells9122704] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
13 Kennedy AJ, Sundström L, Geschwindner S, Poon EKY, Jiang Y, Chen R, Cooke R, Johnstone S, Madin A, Lim J, Liu Q, Lohman RJ, Nordqvist A, Fridén-Saxin M, Yang W, Brown DG, Fairlie DP, Dekker N. Protease-activated receptor-2 ligands reveal orthosteric and allosteric mechanisms of receptor inhibition. Commun Biol 2020;3:782. [PMID: 33335291 DOI: 10.1038/s42003-020-01504-0] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
14 Avet C, Sturino C, Grastilleur S, Gouill CL, Semache M, Gross F, Gendron L, Bennani Y, Mancini JA, Sayegh CE, Bouvier M. The PAR2 inhibitor I-287 selectively targets Gαq and Gα12/13 signaling and has anti-inflammatory effects. Commun Biol 2020;3:719. [PMID: 33247181 DOI: 10.1038/s42003-020-01453-8] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 3.7] [Reference Citation Analysis]
15 Nakashima M, Iohara K, Zayed M. Pulp Regeneration: Current Approaches, Challenges, and Novel Rejuvenating Strategies for an Aging Population. J Endod 2020;46:S135-42. [PMID: 32950185 DOI: 10.1016/j.joen.2020.06.028] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
16 Yesudhas D, Srivastava A, Gromiha MM. COVID-19 outbreak: history, mechanism, transmission, structural studies and therapeutics. Infection 2021;49:199-213. [PMID: 32886331 DOI: 10.1007/s15010-020-01516-2] [Cited by in Crossref: 58] [Cited by in F6Publishing: 43] [Article Influence: 19.3] [Reference Citation Analysis]
17 L'Herondelle K, Pierre O, Fouyet S, Leschiera R, Le Gall-Ianotto C, Philippe R, Buscaglia P, Mignen O, Talagas M, Lewis RJ, Michel L, Misery L, Le Garrec R. PAR2, Keratinocytes, and Cathepsin S Mediate the Sensory Effects of Ciguatoxins Responsible for Ciguatera Poisoning. J Invest Dermatol 2021;141:648-658.e3. [PMID: 32800876 DOI: 10.1016/j.jid.2020.07.020] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
18 Unruh D, Horbinski C. Beyond thrombosis: the impact of tissue factor signaling in cancer. J Hematol Oncol 2020;13:93. [PMID: 32665005 DOI: 10.1186/s13045-020-00932-z] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 7.3] [Reference Citation Analysis]
19 Klösel I, Schmidt MF, Kaindl J, Hübner H, Weikert D, Gmeiner P. Discovery of Novel Nonpeptidic PAR2 Ligands. ACS Med Chem Lett 2020;11:1316-23. [PMID: 32551018 DOI: 10.1021/acsmedchemlett.0c00154] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
20 Gordon DE, Jang GM, Bouhaddou M, Xu J, Obernier K, O'Meara MJ, Guo JZ, Swaney DL, Tummino TA, Hüttenhain R, Kaake RM, Richards AL, Tutuncuoglu B, Foussard H, Batra J, Haas K, Modak M, Kim M, Haas P, Polacco BJ, Braberg H, Fabius JM, Eckhardt M, Soucheray M, Bennett MJ, Cakir M, McGregor MJ, Li Q, Naing ZZC, Zhou Y, Peng S, Kirby IT, Melnyk JE, Chorba JS, Lou K, Dai SA, Shen W, Shi Y, Zhang Z, Barrio-Hernandez I, Memon D, Hernandez-Armenta C, Mathy CJP, Perica T, Pilla KB, Ganesan SJ, Saltzberg DJ, Ramachandran R, Liu X, Rosenthal SB, Calviello L, Venkataramanan S, Lin Y, Wankowicz SA, Bohn M, Trenker R, Young JM, Cavero D, Hiatt J, Roth T, Rathore U, Subramanian A, Noack J, Hubert M, Roesch F, Vallet T, Meyer B, White KM, Miorin L, Agard D, Emerman M, Ruggero D, García-Sastre A, Jura N, von Zastrow M, Taunton J, Schwartz O, Vignuzzi M, d'Enfert C, Mukherjee S, Jacobson M, Malik HS, Fujimori DG, Ideker T, Craik CS, Floor S, Fraser JS, Gross J, Sali A, Kortemme T, Beltrao P, Shokat K, Shoichet BK, Krogan NJ. A SARS-CoV-2-Human Protein-Protein Interaction Map Reveals Drug Targets and Potential Drug-Repurposing. bioRxiv 2020:2020. [PMID: 32511329 DOI: 10.1101/2020.03.22.002386] [Cited by in Crossref: 144] [Cited by in F6Publishing: 33] [Article Influence: 48.0] [Reference Citation Analysis]
21 Rowley JA, Reid RC, Poon EKY, Wu KC, Lim J, Lohman RJ, Hamidon JK, Yau MK, Halili MA, Durek T, Iyer A, Fairlie DP. Potent Thiophene Antagonists of Human Complement C3a Receptor with Anti-Inflammatory Activity. J Med Chem 2020;63:529-41. [PMID: 31910011 DOI: 10.1021/acs.jmedchem.9b00927] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 4.3] [Reference Citation Analysis]
22 Bukowska A, Schild L, Bornfleth P, Peter D, Wiese-Rischke C, Gardemann A, Isermann B, Walles T, Goette A. Activated clotting factor X mediates mitochondrial alterations and inflammatory responses via protease-activated receptor signaling in alveolar epithelial cells. Eur J Pharmacol 2020;869:172875. [PMID: 31877279 DOI: 10.1016/j.ejphar.2019.172875] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
23 Gandhi DM, Rosas R Jr, Greve E, Kentala K, D-R Diby N, Snyder VA, Stephans A, Yeung THW, Subramaniam S, DiMilo E, Kurtenbach KE, Arnold LA, Weiler H, Dockendorff C. The parmodulin NRD-21 is an allosteric inhibitor of PAR1 Gq signaling with improved anti-inflammatory activity and stability. Bioorg Med Chem 2019;27:3788-96. [PMID: 31320211 DOI: 10.1016/j.bmc.2019.06.043] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
24 Schroeder R, Grenning AJ. Accessing the decarboxylative allylation–divinylcyclopropane-cycloheptadiene rearrangement from the ketone/aldehyde substrate pool. Tetrahedron 2019;75:3231-3238. [DOI: 10.1016/j.tet.2019.03.036] [Reference Citation Analysis]
25 Dietz CJ, Sun H, Yao WC, Citardi MJ, Corry DB, Luong AU. Aspergillus fumigatus induction of IL‐33 expression in chronic rhinosinusitis is PAR2‐dependent. The Laryngoscope 2018;129:2230-5. [DOI: 10.1002/lary.28000] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
26 Heuberger DM, Schuepbach RA. Protease-activated receptors (PARs): mechanisms of action and potential therapeutic modulators in PAR-driven inflammatory diseases. Thromb J 2019;17:4. [PMID: 30976204 DOI: 10.1186/s12959-019-0194-8] [Cited by in Crossref: 117] [Cited by in F6Publishing: 125] [Article Influence: 29.3] [Reference Citation Analysis]
27 Conway GD, Buzza MS, Martin EW, Duru N, Johnson TA, Peroutka RJ, Pawar NR, Antalis TM. PRSS21/testisin inhibits ovarian tumor metastasis and antagonizes proangiogenic angiopoietins ANG2 and ANGPTL4. J Mol Med (Berl) 2019;97:691-709. [PMID: 30911775 DOI: 10.1007/s00109-019-01763-3] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
28 Kennedy AJ, Ballante F, Johansson JR, Milligan G, Sundström L, Nordqvist A, Carlsson J. Structural Characterization of Agonist Binding to Protease-Activated Receptor 2 through Mutagenesis and Computational Modeling. ACS Pharmacol Transl Sci 2018;1:119-33. [PMID: 32219208 DOI: 10.1021/acsptsci.8b00019] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
29 Bhuniya D, Bhosale S, Reddy SB, Reddy SN. Isoxazole-tethered diarylheptanoid analogs: Discovery of a new drug-like PAR2 antagonist. Bioorg Med Chem Lett 2018;28:2285-8. [PMID: 29798827 DOI: 10.1016/j.bmcl.2018.05.032] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
30 Ungefroren H, Gieseler F, Kaufmann R, Settmacher U, Lehnert H, Rauch BH. Signaling Crosstalk of TGF-β/ALK5 and PAR2/PAR1: A Complex Regulatory Network Controlling Fibrosis and Cancer. Int J Mol Sci 2018;19:E1568. [PMID: 29795022 DOI: 10.3390/ijms19061568] [Cited by in Crossref: 25] [Cited by in F6Publishing: 27] [Article Influence: 5.0] [Reference Citation Analysis]
31 Gandhi DM, Majewski MW, Rosas R Jr, Kentala K, Foster TJ, Greve E, Dockendorff C. Characterization of Protease-Activated Receptor (PAR) ligands: Parmodulins are reversible allosteric inhibitors of PAR1-driven calcium mobilization in endothelial cells. Bioorg Med Chem 2018;26:2514-29. [PMID: 29685684 DOI: 10.1016/j.bmc.2018.04.016] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
32 Brown DG, Brown GA, Centrella P, Certel K, Cooke RM, Cuozzo JW, Dekker N, Dumelin CE, Ferguson A, Fiez-vandal C, Geschwindner S, Guié M, Habeshian S, Keefe AD, Schlenker O, Sigel EA, Snijder A, Soutter HT, Sundström L, Troast DM, Wiggin G, Zhang J, Zhang Y, Clark MA. Agonists and Antagonists of Protease-Activated Receptor 2 Discovered within a DNA-Encoded Chemical Library Using Mutational Stabilization of the Target. SLAS DISCOVERY: Advancing the Science of Drug Discovery 2018;23:429-36. [DOI: 10.1177/2472555217749847] [Cited by in Crossref: 22] [Cited by in F6Publishing: 25] [Article Influence: 4.4] [Reference Citation Analysis]
33 Jiang Y, Yau MK, Lim J, Wu KC, Xu W, Suen JY, Fairlie DP. A Potent Antagonist of Protease-Activated Receptor 2 That Inhibits Multiple Signaling Functions in Human Cancer Cells. J Pharmacol Exp Ther 2018;364:246-57. [PMID: 29263243 DOI: 10.1124/jpet.117.245027] [Cited by in Crossref: 31] [Cited by in F6Publishing: 35] [Article Influence: 5.2] [Reference Citation Analysis]
34 Yoon H, Radulovic M, Walters G, Paulsen AR, Drucker K, Starski P, Wu J, Fairlie DP, Scarisbrick IA. Protease activated receptor 2 controls myelin development, resiliency and repair. Glia 2017;65:2070-86. [PMID: 28921694 DOI: 10.1002/glia.23215] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 1.8] [Reference Citation Analysis]
35 Artim-Esen B, Smoktunowicz N, McDonnell T, Ripoll VM, Pericleous C, Mackie I, Robinson E, Isenberg D, Rahman A, Ioannou Y, Chambers RC, Giles I. Factor Xa Mediates Calcium Flux in Endothelial Cells and is Potentiated by Igg From Patients With Lupus and/or Antiphospholipid Syndrome. Sci Rep 2017;7:10788. [PMID: 28883515 DOI: 10.1038/s41598-017-11315-9] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
36 Ostertag D, Annahazi A, Krueger D, Michel K, Demir IE, Ceyhan GO, Zeller F, Schemann M. Tryptase potentiates enteric nerve activation by histamine and serotonin: Relevance for the effects of mucosal biopsy supernatants from irritable bowel syndrome patients. Neurogastroenterol Motil 2017;29. [PMID: 28374503 DOI: 10.1111/nmo.13070] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.2] [Reference Citation Analysis]
37 Jiang Y, Yau MK, Kok WM, Lim J, Wu KC, Liu L, Hill TA, Suen JY, Fairlie DP. Biased Signaling by Agonists of Protease Activated Receptor 2. ACS Chem Biol 2017;12:1217-26. [PMID: 28169521 DOI: 10.1021/acschembio.6b01088] [Cited by in Crossref: 27] [Cited by in F6Publishing: 27] [Article Influence: 4.5] [Reference Citation Analysis]
38 Suen J, Adams M, Lim J, Madala P, Xu W, Cotterell A, He Y, Yau M, Hooper J, Fairlie D. Mapping transmembrane residues of proteinase activated receptor 2 (PAR 2 ) that influence ligand-modulated calcium signaling. Pharmacological Research 2017;117:328-42. [DOI: 10.1016/j.phrs.2016.12.020] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.2] [Reference Citation Analysis]
39 Indrakusuma I, Romacho T, Eckel J. Protease-Activated Receptor 2 Promotes Pro-Atherogenic Effects through Transactivation of the VEGF Receptor 2 in Human Vascular Smooth Muscle Cells. Front Pharmacol 2016;7:497. [PMID: 28101054 DOI: 10.3389/fphar.2016.00497] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
40 Yau MK, Liu L, Suen JY, Lim J, Lohman RJ, Jiang Y, Cotterell AJ, Barry GD, Mak JY, Vesey DA, Reid RC, Fairlie DP. PAR2 Modulators Derived from GB88. ACS Med Chem Lett 2016;7:1179-84. [PMID: 27994760 DOI: 10.1021/acsmedchemlett.6b00306] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
41 Ramachandran R, Altier C, Oikonomopoulou K, Hollenberg MD. Proteinases, Their Extracellular Targets, and Inflammatory Signaling. Pharmacol Rev 2016;68:1110-42. [PMID: 27677721 DOI: 10.1124/pr.115.010991] [Cited by in Crossref: 38] [Cited by in F6Publishing: 40] [Article Influence: 5.4] [Reference Citation Analysis]
42 Cho N, Seo S, Kim D, Shin J, Ju J, Seong J, Seo SH, Lee I, Lee K, Kim YK, No KT, Pae AN. Pharmacophore-based virtual screening, biological evaluation and binding mode analysis of a novel protease-activated receptor 2 antagonist. J Comput Aided Mol Des 2016;30:625-37. [DOI: 10.1007/s10822-016-9937-9] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
43 Lieu T, Savage E, Zhao P, Edgington-Mitchell L, Barlow N, Bron R, Poole DP, McLean P, Lohman RJ, Fairlie DP, Bunnett NW. Antagonism of the proinflammatory and pronociceptive actions of canonical and biased agonists of protease-activated receptor-2. Br J Pharmacol 2016;173:2752-65. [PMID: 27423137 DOI: 10.1111/bph.13554] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 1.9] [Reference Citation Analysis]
44 Stahn S, Thelen L, Albrecht IM, Bitzer J, Henkel T, Teusch NE. Teleocidin A2 inhibits human proteinase-activated receptor 2 signaling in tumor cells. Pharmacol Res Perspect 2016;4:e00230. [PMID: 28116092 DOI: 10.1002/prp2.230] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
45 Abulkassim R, Brett R, Mackenzie SM, Bushell TJ. Proteinase-activated receptor 2 is involved in the behavioural changes associated with sickness behaviour. Journal of Neuroimmunology 2016;295-296:139-47. [DOI: 10.1016/j.jneuroim.2016.04.016] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
46 Yau MK, Lim J, Liu L, Fairlie DP. Protease activated receptor 2 (PAR2) modulators: a patent review (2010-2015). Expert Opin Ther Pat 2016;26:471-83. [PMID: 26936077 DOI: 10.1517/13543776.2016.1154540] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 2.7] [Reference Citation Analysis]
47 Kagota S, Maruyama K, McGuire JJ. Characterization and Functions of Protease-Activated Receptor 2 in Obesity, Diabetes, and Metabolic Syndrome: A Systematic Review. Biomed Res Int 2016;2016:3130496. [PMID: 27006943 DOI: 10.1155/2016/3130496] [Cited by in Crossref: 19] [Cited by in F6Publishing: 21] [Article Influence: 2.7] [Reference Citation Analysis]
48 Yau M, Liu L, Lim J, Lohman R, Cotterell AJ, Suen JY, Vesey DA, Reid RC, Fairlie DP. Benzylamide antagonists of protease activated receptor 2 with anti-inflammatory activity. Bioorganic & Medicinal Chemistry Letters 2016;26:986-91. [DOI: 10.1016/j.bmcl.2015.12.048] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
49 Yau MK, Suen JY, Xu W, Lim J, Liu L, Adams MN, He Y, Hooper JD, Reid RC, Fairlie DP. Potent Small Agonists of Protease Activated Receptor 2. ACS Med Chem Lett 2016;7:105-10. [PMID: 26819675 DOI: 10.1021/acsmedchemlett.5b00429] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.9] [Reference Citation Analysis]
50 Cho N, Cha JH, Kim H, Kwak J, Kim D, Seo S, Shin J, Kim T, Park KD, Lee J, No KT, Kim YK, Lee K, Pae AN. Discovery of 2-aryloxy-4-amino-quinazoline derivatives as novel protease-activated receptor 2 (PAR2) antagonists. Bioorganic & Medicinal Chemistry 2015;23:7717-27. [DOI: 10.1016/j.bmc.2015.11.016] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
51 Xu W, Lim J, Goh C, Suen JY, Jiang Y, Yau M, Wu K, Liu L, Fairlie DP. Repurposing Registered Drugs as Antagonists for Protease-Activated Receptor 2. J Chem Inf Model 2015;55:2079-84. [DOI: 10.1021/acs.jcim.5b00500] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
52 Boitano S, Hoffman J, Flynn AN, Asiedu MN, Tillu DV, Zhang Z, Sherwood CL, Rivas CM, DeFea KA, Vagner J, Price TJ. The novel PAR2 ligand C391 blocks multiple PAR2 signalling pathways in vitro and in vivo. Br J Pharmacol 2015;172:4535-45. [PMID: 26140338 DOI: 10.1111/bph.13238] [Cited by in Crossref: 29] [Cited by in F6Publishing: 32] [Article Influence: 3.6] [Reference Citation Analysis]
53 Muley MM, Reid AR, Botz B, Bölcskei K, Helyes Z, McDougall JJ. Neutrophil elastase induces inflammation and pain in mouse knee joints via activation of proteinase-activated receptor-2. Br J Pharmacol 2016;173:766-77. [PMID: 26140667 DOI: 10.1111/bph.13237] [Cited by in Crossref: 43] [Cited by in F6Publishing: 46] [Article Influence: 5.4] [Reference Citation Analysis]
54 Vilums M, Heuberger J, Heitman LH, IJzerman AP. Indanes--Properties, Preparation, and Presence in Ligands for G Protein Coupled Receptors. Med Res Rev 2015;35:1097-126. [PMID: 26018667 DOI: 10.1002/med.21352] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 3.0] [Reference Citation Analysis]
55 Perry SR, Xu W, Wirija A, Lim J, Yau MK, Stoermer MJ, Lucke AJ, Fairlie DP. Three Homology Models of PAR2 Derived from Different Templates: Application to Antagonist Discovery. J Chem Inf Model 2015;55:1181-91. [PMID: 26000704 DOI: 10.1021/acs.jcim.5b00087] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 1.8] [Reference Citation Analysis]
56 Christensen J, Alfredson H, Andersson G. Protease-activated receptors in the Achilles tendon-a potential explanation for the excessive pain signalling in tendinopathy. Mol Pain 2015;11:13. [PMID: 25880199 DOI: 10.1186/s12990-015-0007-4] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
57 McDougall JJ, Muley MM. The role of proteases in pain. Handb Exp Pharmacol 2015;227:239-60. [PMID: 25846622 DOI: 10.1007/978-3-662-46450-2_12] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 1.5] [Reference Citation Analysis]
58 Kakarala KK, Jamil K. Protease activated receptor-2 (PAR2): possible target of phytochemicals. J Biomol Struct Dyn 2015;33:2003-22. [PMID: 25386994 DOI: 10.1080/07391102.2014.986197] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
59 Alexander SP, Benson HE, Faccenda E, Pawson AJ, Sharman JL, Spedding M, Peters JA, Harmar AJ; CGTP Collaborators. The Concise Guide to PHARMACOLOGY 2013/14: G protein-coupled receptors. Br J Pharmacol 2013;170:1459-581. [PMID: 24517644 DOI: 10.1111/bph.12445] [Cited by in Crossref: 508] [Cited by in F6Publishing: 514] [Article Influence: 56.4] [Reference Citation Analysis]
60 Bell A, Althaus M, Diener M. Communication between mast cells and rat submucosal neurons. Pflugers Arch - Eur J Physiol 2015;467:1809-23. [DOI: 10.1007/s00424-014-1609-9] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 1.6] [Reference Citation Analysis]
61 Kakarala KK, Jamil K, Devaraji V. Structure and putative signaling mechanism of Protease activated receptor 2 (PAR2) - a promising target for breast cancer. J Mol Graph Model 2014;53:179-99. [PMID: 25173751 DOI: 10.1016/j.jmgm.2014.07.012] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 1.9] [Reference Citation Analysis]
62 Suen JY, Cotterell A, Lohman RJ, Lim J, Han A, Yau MK, Liu L, Cooper MA, Vesey DA, Fairlie DP. Pathway-selective antagonism of proteinase activated receptor 2. Br J Pharmacol 2014;171:4112-24. [PMID: 24821440 DOI: 10.1111/bph.12757] [Cited by in Crossref: 46] [Cited by in F6Publishing: 48] [Article Influence: 5.1] [Reference Citation Analysis]
63 Boitano S, Hoffman J, Tillu DV, Asiedu MN, Zhang Z, Sherwood CL, Wang Y, Dong X, Price TJ, Vagner J. Development and evaluation of small peptidomimetic ligands to protease-activated receptor-2 (PAR2) through the use of lipid tethering. PLoS One 2014;9:e99140. [PMID: 24927179 DOI: 10.1371/journal.pone.0099140] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 1.6] [Reference Citation Analysis]
64 Görgens SW, Eckardt K, Elsen M, Tennagels N, Eckel J. Chitinase-3-like protein 1 protects skeletal muscle from TNFα-induced inflammation and insulin resistance. Biochem J 2014;459:479-88. [PMID: 24512683 DOI: 10.1042/BJ20131151] [Cited by in Crossref: 42] [Cited by in F6Publishing: 46] [Article Influence: 4.7] [Reference Citation Analysis]
65 Saaber D, Wollenhaupt S, Baumann K, Reichl S. Recent progress in tight junction modulation for improving bioavailability. Expert Opin Drug Discov 2014;9:367-81. [PMID: 24558958 DOI: 10.1517/17460441.2014.892070] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 1.9] [Reference Citation Analysis]
66 Lim J, Iyer A, Liu L, Suen JY, Lohman RJ, Seow V, Yau MK, Brown L, Fairlie DP. Diet-induced obesity, adipose inflammation, and metabolic dysfunction correlating with PAR2 expression are attenuated by PAR2 antagonism. FASEB J. 2013;27:4757-4767. [PMID: 23964081 DOI: 10.1096/fj.13-232702] [Cited by in Crossref: 72] [Cited by in F6Publishing: 75] [Article Influence: 7.2] [Reference Citation Analysis]
67 Yau MK, Liu L, Fairlie DP. Toward drugs for protease-activated receptor 2 (PAR2). J Med Chem 2013;56:7477-97. [PMID: 23895492 DOI: 10.1021/jm400638v] [Cited by in Crossref: 61] [Cited by in F6Publishing: 64] [Article Influence: 6.1] [Reference Citation Analysis]
68 Hughes KH, Wijekoon EP, Valcour JE, Chia EW, Mcguire JJ. Effects of chronic in-vivo treatments with protease-activated receptor 2 agonist on endothelium function and blood pressures in mice. Can J Physiol Pharmacol 2013;91:295-305. [DOI: 10.1139/cjpp-2012-0266] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
69 Hennessey JC, McGuire JJ. Attenuated vasodilator effectiveness of protease-activated receptor 2 agonist in heterozygous par2 knockout mice. PLoS One 2013;8:e55965. [PMID: 23409098 DOI: 10.1371/journal.pone.0055965] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
70 Flynn AN, Hoffman J, Tillu DV, Sherwood CL, Zhang Z, Patek R, Asiedu MN, Vagner J, Price TJ, Boitano S. Development of highly potent protease-activated receptor 2 agonists via synthetic lipid tethering. FASEB J 2013;27:1498-510. [PMID: 23292071 DOI: 10.1096/fj.12-217323] [Cited by in Crossref: 23] [Cited by in F6Publishing: 24] [Article Influence: 2.3] [Reference Citation Analysis]
71 Vesey DA, Suen JY, Seow V, Lohman RJ, Liu L, Gobe GC, Johnson DW, Fairlie DP. PAR2-induced inflammatory responses in human kidney tubular epithelial cells. Am J Physiol Renal Physiol 2013;304:F737-50. [PMID: 23283995 DOI: 10.1152/ajprenal.00540.2012] [Cited by in Crossref: 29] [Cited by in F6Publishing: 30] [Article Influence: 2.9] [Reference Citation Analysis]
72 Wu Y, Zhang X, Zhou H, Chen D, Xie H, Mu Y, Wu B, Yan J. Factor VIIa regulates the expression of caspase-3, MMP-9, and CD44 in SW620 colon cancer cells involving PAR2/MAPKs/NF-κB signaling pathways. Cancer Invest 2013;31:7-16. [PMID: 23170789 DOI: 10.3109/07357907.2012.743556] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 1.5] [Reference Citation Analysis]
73 Suen JY, Barry GD, Lohman RJ, Halili MA, Cotterell AJ, Le GT, Fairlie DP. Modulating human proteinase activated receptor 2 with a novel antagonist (GB88) and agonist (GB110). Br J Pharmacol 2012;165:1413-23. [PMID: 21806599 DOI: 10.1111/j.1476-5381.2011.01610.x] [Cited by in Crossref: 84] [Cited by in F6Publishing: 87] [Article Influence: 7.6] [Reference Citation Analysis]
74 Caliendo G, Santagada V, Perissutti E, Severino B, Fiorino F, Frecentese F, Juliano L. Kallikrein protease activated receptor (PAR) axis: an attractive target for drug development. J Med Chem 2012;55:6669-86. [PMID: 22607152 DOI: 10.1021/jm300407t] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 1.4] [Reference Citation Analysis]
75 Crilly A, Palmer H, Nickdel MB, Dunning L, Lockhart JC, Plevin R, McInnes IB, Ferrell WR. Immunomodulatory role of proteinase-activated receptor-2. Ann Rheum Dis 2012;71:1559-66. [PMID: 22563031 DOI: 10.1136/annrheumdis-2011-200869] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 1.6] [Reference Citation Analysis]
76 Lohman RJ, Cotterell AJ, Barry GD, Liu L, Suen JY, Vesey DA, Fairlie DP. An antagonist of human protease activated receptor-2 attenuates PAR2 signaling, macrophage activation, mast cell degranulation, and collagen-induced arthritis in rats. FASEB J. 2012;26:2877-2887. [PMID: 22467762 DOI: 10.1096/fj.11-201004] [Cited by in Crossref: 77] [Cited by in F6Publishing: 79] [Article Influence: 7.0] [Reference Citation Analysis]
77 Stoermer MJ, Flanagan B, Beyer RL, Madala PK, Fairlie DP. Structures of peptide agonists for human protease activated receptor 2. Bioorg Med Chem Lett 2012;22:916-9. [PMID: 22209488 DOI: 10.1016/j.bmcl.2011.12.029] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
78 Ramachandran R, Noorbakhsh F, Defea K, Hollenberg MD. Targeting proteinase-activated receptors: therapeutic potential and challenges. Nat Rev Drug Discov 2012;11:69-86. [PMID: 22212680 DOI: 10.1038/nrd3615] [Cited by in Crossref: 233] [Cited by in F6Publishing: 240] [Article Influence: 21.2] [Reference Citation Analysis]
79 Kaufmann R, Hollenberg MD. Proteinase-Activated Receptors (PARs) and Calcium Signaling in Cancer. Advances in Experimental Medicine and Biology 2012. [DOI: 10.1007/978-94-007-2888-2_45] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 1.3] [Reference Citation Analysis]
80 Georgy SR, Pagel CN, Ghasem-Zadeh A, Zebaze RM, Pike RN, Sims NA, Mackie EJ. Proteinase-activated receptor-2 is required for normal osteoblast and osteoclast differentiation during skeletal growth and repair. Bone 2012;50:704-12. [PMID: 22173052 DOI: 10.1016/j.bone.2011.11.023] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 1.9] [Reference Citation Analysis]
81 Lohman RJ, Cotterell AJ, Suen J, Liu L, Do AT, Vesey DA, Fairlie DP. Antagonism of protease-activated receptor 2 protects against experimental colitis. J Pharmacol Exp Ther. 2012;340:256-265. [PMID: 22028393 DOI: 10.1124/jpet.111.187062] [Cited by in Crossref: 74] [Cited by in F6Publishing: 77] [Article Influence: 6.2] [Reference Citation Analysis]
82 Rothmeier AS, Ruf W. Protease-activated receptor 2 signaling in inflammation. Semin Immunopathol. 2012;34:133-149. [PMID: 21971685 DOI: 10.1007/s00281-011-0289-1] [Cited by in Crossref: 203] [Cited by in F6Publishing: 208] [Article Influence: 16.9] [Reference Citation Analysis]
83 Adams MN, Ramachandran R, Yau MK, Suen JY, Fairlie DP, Hollenberg MD, Hooper JD. Structure, function and pathophysiology of protease activated receptors. Pharmacol Ther 2011;130:248-82. [PMID: 21277892 DOI: 10.1016/j.pharmthera.2011.01.003] [Cited by in Crossref: 264] [Cited by in F6Publishing: 268] [Article Influence: 22.0] [Reference Citation Analysis]
84 Hollenberg MD, Hansen KK, Mihara K, Ramachandran R. Proteolytic Enzymes and Cell Signaling: Pharmacological Lessons. Proteases and Their Receptors in Inflammation 2011. [DOI: 10.1007/978-3-0348-0157-7_1] [Reference Citation Analysis]